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The association between the staging of colorectal cancer and mortality is well known. Much less researched is the relationship
between the duration of symptoms and outcome, and whether particular initial symptoms carry a different prognosis. We performed
a cohort study of 349 patients with primary colorectal cancer in whom all their prediagnostic symptoms and investigation results were
known. Survival data for 3–8 years after diagnosis were taken from the cancer registry. Six features were studied: rectal bleeding,
abdominal pain, diarrhoea, constipation, weight loss, and anaemia. Two of these were significantly associated with different staging and
mortality. Rectal bleeding as an initial symptom was associated with less advanced staging (odds ratio from one Duke’s stage to the
next 0.50, 95% confidence interval 0.31, 0.79; P¼ 0.003) and with reduced mortality (Cox’s proportional hazard ratio (HR) 0.56
(0.41, 0.79); P¼ 0.001. Mild anaemia, with a haemoglobin of 10.0–12.9 g dl1, was associated with more advanced staging (odds ratio
2.2 (1.2, 4.3); P¼ 0.021) and worse mortality (HR 1.5 (0.98, 2.3): P¼ 0.064). When corrected for emergency admission, sex, and the
site of the tumour, the HR for mild anaemia was 1.7 (1.1, 2.6); P¼ 0.015. No relationship was found between the duration of
symptoms and staging or mortality.
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It is generally assumed that making a diagnosis of colorectal
cancer as early as possible is beneficial. Earlier diagnosis can arise
from screening or improved recognition of symptomatic cancers.
In the UK, approximately three-quarters of colorectal cancers
present initially to their general practitioner (GP) with non-
emergency symptoms, such as rectal bleeding, abdominal pain, or
change in bowel habit (Barrett et al, 2006). Even after the proposed
introduction of screening in the UK in 2006, it is likely that the
majority of patients will still present with symptoms (Hamilton
et al, 2005).
Patients who attend primary care in the UK with clinical features
suggesting possible colorectal cancer can be referred to a rapid
investigation facility, ‘the 2-week clinic.’ Referral guidance for
these clinics outlines clinical scenarios deemed to carry sufficient
risk to warrant rapid investigation. (NICE, 2005) The assumption
behind these clinics is that cancers have a symptomatic phase of
sufficient duration to offer the possibility of earlier diagnosis,
leading to mortality benefits. This assumption can be explored by
examination of the relationships between mortality (or staging)
and the duration of symptoms. Several such studies have been
reported. There is a clear relationship between the staging of the
cancer and mortality (Mulcahy and O’Donoghue, 1997; Roncoroni
et al, 1999; Ponz de Leon et al, 2000; Gonzalez-Hermoso et al, 2004;
Olsson et al, 2004). Conversely, most studies have shown no
relationship between the duration of symptoms and staging or
mortality (Stubbs and Long, 1986; Barillari et al, 1989; Kyle et al,
1991; Mulcahy and O’Donoghue, 1997; Majumdar et al, 1999;
Roncoroni et al, 1999; Kiran and Glass, 2002; Gonzalez-Hermoso
et al, 2004; Olsson et al, 2004; Bharucha et al, 2005; Khattak et al,
2006; Rupassara et al, 2006). Some have reported an inverse
relationship, with a shorter duration of symptoms being associated
with both worse staging and worse prognosis (Mulcahy and
O’Donoghue, 1997; Olsson et al, 2004; Rupassara et al, 2006).
Once emergency admissions, which generally have a shorter
duration of symptoms, are corrected for, this inverse relationship
disappears (Mulcahy and O’Donoghue, 1997; Olsson et al, 2004;
Rupassara et al, 2006). Only two previous studies have examined
the relationship between the first symptom of the cancer and
mortality (Gonzalez-Hermoso et al, 2004; Korsgaard et al, 2006).
However, all these previous studies have either dated the onset
of symptoms from the dates given in the doctor’s referral letter,
or by interviewing patients after the diagnosis had been made.
These methods are prone to inaccuracy, with some patients able
only to specify the calendar year that their symptoms began, and
others giving illogical dates of onset, such as dates after their
diagnosis had been made (Olsson et al, 2004). Furthermore, only
two studies were community based, including all cases from a
specific area (Olsson et al, 2004; Korsgaard et al, 2006). The
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remainder were hospital-based, raising the possibility that cases
referred to that hospital were not typical of the whole colorectal
cancer population.
We sought to address these methodological issues by an analysis
of a cohort of 349 patients with colorectal cancers occurring in
a 5-year period from Exeter, Devon, UK (Hamilton et al, 2005).
In this cohort, all symptoms recorded in primary care before
diagnosis were collected and coded systematically. This methodo-
logy eliminates concerns about the accuracy of patient recall,
although it does not address symptoms experienced but not
reported to primary care.
MATERIALS AND METHODS
Participants
We studied subjects from a previously described population-based
case–control study (Hamilton et al, 2005). In that study, all 358
primary colorectal cancer cases in patients aged 40 years or more
from Exeter Primary Care Trust (PCT), diagnosed between 1998
and 2002, were identified from the local cancer registry. This list
was augmented by computer searches at all 21 general practices in
the PCT, identifying a further three cases. Twelve of the total 361
cases could not be studied as they had either died (five) or left
Exeter (seven), and their primary care records were unobtainable.
Therefore, 349 cases with full primary care records were studied,
141 (40%) of whom had also died by the time of the initial study,
but whose records were retrievable. Emergency presentations were
defined as those requiring surgical admission for suspected bowel
obstruction or perforation, and who had their cancer diagnosed
during the admission, almost always at laparotomy. The entire
primary care record for the 2 years preceding diagnosis for
all subjects was coded using the International Classification of
Primary Care-2, (WONCA, 1998) although for this paper only data
from the year before diagnosis were used. The second year before
diagnosis was omitted because the rate of reporting of the various
clinical features was similar in both cases and controls for that
year, so reporting of features in that year by cases would probably
be unrelated to their future cancer (Hamilton et al, 2005).
Survival data were obtained from the cancer registry, up to the 8
December 2005, so were available for between 3 and 8 years.
Deaths are routinely notified to the registry. Almost all cancer-
related therapy for patients in Exeter PCT takes place at the Royal
Devon and Exeter Hospital: attendances to this hospital are also
reported to the cancer registry. The last hospital attendance was
taken as the last date in which the patient was known to be alive. In
13 patients who had no hospital attendances recorded, nor had
been reported dead, their vital status was ascertained from the
Patient and Practitioner Services Agency: one patient’s details
could not be found there, and her status was obtained by direct
enquiry at her general practice.
Clinical features studied
Ten clinical features had been identified as being independently
associated with the diagnosis of colorectal cancer: rectal bleeding,
abdominal pain, diarrhoea, constipation, weight loss, abdominal
tenderness, anaemia (haemoglobin below 13 g dl1), abnormal
rectal examination, a blood sugar level over 10 mm l1, and a
positive faecal occult blood testing (Hamilton et al, 2005). For this
analysis, only the five symptoms and one investigation, anaemia,
were included. For simplicity, these are called features from now
on, with the index feature being the first one present. Three of the
other four features: abdominal tenderness, a rectal mass, and a
positive faecal occult blood test, would generally be expected to be
identified only in patients who had described a symptom. It was
therefore more appropriate to study the symptom itself. The final
feature associated with colorectal cancer was a raised blood sugar.
Clinically, this finding would be of little practical value in
identifying symptomatic colorectal cancer, so it was not studied
here. Furthermore, the six selected features mirror those used in
previous studies, allowing comparisons to be made.
Analyses
Two research questions were investigated. The first was that the
staging and/or mortality of patients would differ depending on the
index feature the patient had experienced in the year before
diagnosis. Differences in staging by index feature were analysed
using ordinal regression. Initially, this was a univariable analysis,
which was followed by adding age and sex and emergency
admission to the models. In a small number of patients the Duke’s
staging was unknown. The cancer registry considered that the
commonest cause of absent staging was most likely to be because
the patient had disseminated disease, with laparotomy and formal
staging not having been undertaken. Therefore, a second analysis
was conducted, adding the patients whose staging was unknown
to the Dukes’ D group. Mortality by index feature was analysed
using Cox’s proportional hazards regression model. Following a
univariable analysis, multivariable Cox regression added the
possible confounders of sex, tumour site (to the right of the
splenic flexure, or from the splenic flexure to the rectum), and
emergency admission. If multiple features were present at the
index consultation, the patient was included under each one.
The second issue was that staging and/or mortality would be
related to the duration of symptoms, duration being defined as the
interval from presentation of the index feature to diagnosis. This
was analysed by dividing the duration into approximate quartiles:
1–30, 31–90, 91–180, and 181–365 days before diagnosis. Cox’s
proportional hazards regression was used to analyse the relation-
ship between duration of symptoms and mortality. The above
analyses were then repeated with age, staging, and emergency
admissions added to the models. Again, patients with absent staging
were added to the Duke’s D group and the analyses repeated.
RESULTS
The cohort contained 349 patients with colorectal cancer. Details
of their clinical features, their staging, and whether they had
an emergency presentation are shown in Table 1. Age and sex
distributions were similar between elective and emergency
presentations: P¼ 0.65 (Wilcoxon test) and 0.21 (w2), respectively.
There was also no relationship between age and staging: P¼ 0.35
(median test). This remained so even when the unknown staging
cases were added to Duke’s D group. Similarly, there was no
relationship between sex and staging: P¼ 0.91 (w2) again without a
material difference when the unknown staging cases were added to
the Duke’s D group. Three hundred and nineteen of the 349 cases
had reported one of the features: of these 319, a single feature was
noted at the index consultation in 255 (73%), two features in 50
(14%), and three or more in 14 (4%). In the 319 cases with one of
the features, the median time this feature was noted was 97 days
before diagnosis (interquartile range (IQR) 44, 218).
Initial symptoms and staging
The Duke’s staging in relation to the initial symptoms is shown
in Table 2. The ordinal regressions suggested two initial features
were associated with different staging. The first was rectal bleeding
with an odds ratio of 0.50 (95% confidence interval 0.31, 0.79),
P¼ 0.003, meaning that rectal bleeding was associated with earlier
staging. The second feature was mild anaemia with an odds ratio of
2.2 (1.2, 4.3), P¼ 0.021, meaning mild anaemia was associated with
later staging. These results were almost unchanged if the patients
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with unknown staging were added to the Duke’s D group, or
when age, sex, or emergency admission status were added to the
models.
Initial symptoms and mortality
Of the 349 cases, 207 (59%) had died by the date of this study. The
deaths had occurred a median 421 (IQR 102, 841) days after
diagnosis. Follow-up data were available in survivors for a median
1592 (1193, 2001) days after diagnosis. There was no relationship
between the number of symptoms recorded at the index
consultation and mortality (Table 3).
Staging and mortality in relation to the duration of
symptoms
Of the 319 patients with at least one feature of cancer present in the
notes, the first feature was recorded between 30 days and 1 day
before diagnosis in 61 patients (17% of the cohort), between 31 and
90 days in 92 patients (26%), between 91 and 180 days in 62 patients
(18%) and between 181 and 365 days in 104 (30%) (Table 4).
There was no apparent relationship between the duration of
symptom in quartiles and staging: P¼ 0.27 (w2 test, 12 degrees of
freedom (d.f.)). This finding was unchanged if those with unknown
staging were added to the Duke’s D group; P¼ 0.67 (w2 test, 9 d.f.).
Mortality in relation to symptom duration is shown in Figure 1.
There was no relationship between the duration of symptoms and
mortality: P¼ 0.47 (Cox proportional hazards). In a multivariable
model including symptom duration, there was a relationship
between mortality and emergency admission (hazard ratio (HR)
1.9: Po0.001), age (HR 1.03 for each year older: Po0.001), and
staging (HR 1.5 for each increase in stage: Po0.001). In this model,
left-sided tumours had a survival advantage of marginal sig-
nificance (HR 0.75: P¼ 0.059) but again symptom duration was
not associated with mortality (HR 1.0: P¼ 0.11).
DISCUSSION
The main findings from this study are that the mortality from
colorectal cancer differs depending upon the nature of the first
Table 1 Details of the age, sex, emergency presentation, and clinical features of the cohort
Number
(% of cohort)
Median (IQR)
age
Number (%)
male
Median (IQR) days
before diagnosis
Entire cohort 349 (100) 73 (65,81) 177 (51)
Emergency presentations 62 (18) 75 (65,84) 27 (44)
Duke’s staging A 48 72 (64,80) 25 (52)
B 130 75 (66,82) 62 (48)
C 100 73 (65,80) 52 (52)
D 46 70 (64,78) 23 (50)
Unknown 25 77 (71,83) 15 (60)
First symptom noted Rectal bleeding 97 (28) 73 (64,81) 56 (58) 64 (29, 133)
Abdominal pain 82 (24) 70 (61,79) 42 (51) 133 (49, 221)
Diarrhoea 76 (22) 70 (61,78) 35 (46) 98 (38, 217)
Constipation 38 (11) 75 (67,81) 22 (58) 126 (59, 222)
Loss of weight 26 (7) 75 (65,82) 8 (31) 55 (31, 170)
Mild anaemia 37 (11) 74 (67,80) 20 (54) 133 (81, 305)
Severe anaemia 43 (12) 79 (75,85) 18 (42) 100 (36, 218)
Symptoms noted at any time before diagnosis Rectal bleeding 136 (39) 73 (65,81) 77 (57) 65 (29, 129)
Abdominal pain 131 (38) 71 (62,79) 60 (46) 85 (36, 194)
Diarrhoea 113 (32) 73 (64,79) 51 (45) 78 (33, 181)
Constipation 80 (23) 73 (63,81) 38 (48) 70 (16, 144)
Loss of weight 80 (23) 72 (64,80) 34 (43) 47 (20, 104)
Mild anaemiaa 80 (23) 73 (67,81) 40 (50) 93 (42, 200)
Severe anaemiaa 73 (21) 79 (73,84) 30 (41) 85 (23,168)
IQR¼ interquartile range. aTwenty-three of these patients had both mild and severe anaemia at some point before diagnosis. Mild anaemia defined as a haemoglobin 10.0–
12.9 g dl1, severe as¼o9.9 g dl1.
Table 2 Duke’s staging in relation to the first symptom
Number (%) with each Duke’s staging
First symptom A B C D Not known P-value*
Rectal bleeding 8 (8) 24 (25) 31 (32) 27 (28) 7 (7) 0.003
Abdominal pain 6 (7) 7 (9) 35 (43) 23 (28) 11 (13) 0.59
Diarrhoea 4 (5) 7 (9) 32 (42) 22 (29) 11 (14) 0.50
Constipation 2 (5) 5 (13) 17 (45) 9 (24) 5 (13) 0.64
Loss of weight 0 2 (8) 14 (54) 6 (23) 4 (15) 0.98
Mild anaemia 3 (8) 3 (8) 11 (30) 10 (27) 10 (27) 0.021
Severe anaemia 4 (9) 3 (7) 18 (42) 14 (33) 4 (9) 0.73
*By ordinal regression.
Table 3 Mortality in relation to the first symptom
Univariable Multivariablea
First symptom
Proportional
hazard (CI) P-value
Proportional
hazard (CI) P-value
Rectal bleeding 0.56 (0.41, 0.79) 0.001 0.57 (0.41, 0.81) 0.001
Abdominal pain 1.3 (0.93, 1.7) 0.14 1.3 (0.95, 1.8) 0.096
Diarrhoea 0.93 (0.67, 1.3) 0.70 1.1 (0.77, 1.5) 0.63
Constipation 1.3 (0.84, 1.9) 0.27 1.1 (0.79, 1.8) 0.60
Loss of weight 1.5 (0.94, 2.4) 0.092 1.5 (0.91, 2.3) 0.11
Mild anaemia 1.5 (0.98, 2.3) 0.064 1.8 (1.1, 2.7) 0.010
Severe anaemia 0.98 (0.65, 1.5) 0.93 0.79 (0.51, 1.2) 0.30
CI, confidence interval. aOther variables in model: age, emergency admission status,
sex, and site of tumour.
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clinical feature reported to primary care. Patients who experience
rectal bleeding have a lower mortality, whereas those who have
mild anaemia have a higher mortality. In contrast to these
findings, no relationship was found between the duration of
symptoms and mortality, even when corrected for possible
confounders, such as having an emergency admission.
Strengths and weaknesses
This is a large community-based study without recall bias, and
with no patients lost to follow-up. Even so, some of the subgroups
contained relatively small numbers, reducing power for some of
the analyses. It is the first study to use contemporary medical
records to validate patients’ symptom experiences before colo-
rectal cancer is diagnosed. As such, identifying the interval
between symptom reporting and diagnosis is probably more
accurate than in previous studies, all of which have relied upon
patient recall. There are three caveats, however. Firstly, patients
may have experienced symptoms, yet not reported them to the
doctor. This may be relatively unimportant in terms of reducing
delay in investigation, as current initiatives are based on expedi-
ting the diagnostic process once a symptom has been presented,
rather than encouraging earlier presentation of symptoms by
patients. The second caveat is that patients may have described
symptoms to their doctors, which then went unrecorded. We
cannot know how often this happened, but it is encouraging that
the incidence of rectal bleeding reports in the original study
matched previous reports almost exactly (Hamilton et al, 2005).
The third caveat is that we defined the first symptom occurring in
the year before diagnosis as being the index symptom. Some of
these first symptoms – abdominal pain in particular – may have
been unrelated to the cancer. However, less than one in ten healthy
patients report abdominal pain to primary care in any 2-year
period, (Hamilton et al, 2005) so it is unlikely that more than a few
of the 131 (38%) of patients in whom abdominal pain was the first
feature noted were in fact misclassified.
Comparison of findings with previous literature
This study is very similar to previous series in terms of symptoms
reported by patients. The staging of the tumours and the
proportions with left- or right-sided tumours or with emergency
admissions are also similar. The finding of no relationship between
the duration of symptoms and staging or mortality – even with our
robust methods of identifying the duration – matches previous
reports (Stubbs and Long, 1986; Barillari et al, 1989; Kyle et al,
1991; Mulcahy and O’Donoghue, 1997; Majumdar et al, 1999;
Roncoroni et al, 1999; Kiran and Glass, 2002; Gonzalez-Hermoso
et al, 2004; Olsson et al, 2004; Bharucha et al, 2005; Khattak et al,
2006; Rupassara et al, 2006). It is likely that two effects are
cancelling each other out: inherent biological features of the
tumour and ease of diagnosis. It is likely that there exists a
spectrum of biological aggressiveness of the tumour, containing a
subgroup of slow-growing tumours with a long duration of
symptoms (Jones et al, 2001). These cancers would be expected to
have favourable staging and mortality, but their symptoms may be
vague or atypical, delaying the diagnosis. In this study, nearly half
of all patients had symptoms of their cancer not only reported to
their doctor, but deemed worthy of record, at least 90 days before
the diagnosis. It is possible that advancing the date of diagnosis by
even half of that time would yield a mortality benefit, irrespective
of any issue of underlying tumour aggressiveness, perhaps by
avoidance of emergency admissions in some patients.
The associations between rectal bleeding as an initial symptom
and better mortality, and between mild anaemia and worse
mortality are important findings. The only other studies to
examine outcomes in relation to the initial symptom reported
better staging with rectal bleeding (Gonzalez-Hermoso et al, 2004;
Korsgaard et al, 2006), and worse staging with either abdominal
pain or anaemia (though anaemia was described in that paper as a
symptom, rather than being confirmed by estimation of the
haemoglobin, as in the study reported here) (Gonzalez-Hermoso
et al, 2004). The mortality in relation to these symptoms was not
reported in either previous paper, though it would be expected to
mirror the staging differences (Gonzalez-Hermoso et al, 2004;
Korsgaard et al, 2006).
Why is rectal bleeding as an initial symptom linked with a good
prognosis and anaemia with a poor prognosis? The associations
remained present even once the recognised confounders of
emergency admission, sex, and the site of the tumour were added
to the model, so these variables cannot explain the results. There
are two likely explanations. The first possible explanation is that
anaemia arises from colorectal cancers as a result of persistent,
occult, bleeding into the gastrointestinal tract, so the bleeding (and
the tumour) will have been present for some time, perhaps
months. In contrast, overt rectal bleeding may occur early in the
development of the tumour. A second possibility is that doctors
are more alert to the possibility of cancer with rectal bleeding and
Table 4 Duke’s staging in relation to the duration of symptoms
Number (%) with each Duke’s staging
Date of first symptom related to date of diagnosis Number A B C D Not known
1–30 days 61 8 (13) 23 (38) 19 (31) 6 (10) 5 (8)
31–90 days 92 13 (14) 30 (33) 29 (32) 13 (14) 7 (8)
91–180 days 62 5 (8) 30 (48) 18 (29) 9 (15) 0
181–365 days 104 17 (16) 41 (39) 25 (24) 9 (9) 12 (12)
Total 319 43 (13) 124 (39) 91 (29) 37 (12) 24 (8)
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Figure 1 Kaplan–Meier survival estimates in relation to symptom
duration.
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choose to investigate (du Toit et al, 2006), even though current
guidance suggests 6 weeks of isolated bleeding is required to
warrant urgent investigation (NICE, 2005). Although severe
anaemia is recognised as a feature of possible colorectal cancer,
with a risk of approximately 7% (Logan et al, 2002; NICE, 2005), it
is still under-investigated in around half of primary care patients.
Mild anaemia, with haemoglobin values in the range 10.0–
12.9 g dl1, is common in the elderly population, but carries a
risk of colorectal cancer of around 1% (Hamilton et al, 2005).
Many GPs would not even consider the possibility of cancer with
such mild anaemia – and others may consider investigation of the
gastrointestinal tract inappropriate when the risk is relatively low.
Nonetheless, it is likely that our finding of increased mortality
from colorectal cancer when anaemia is the initial feature will be
perpetuated unless doctors change their investigatory behaviour.
Testing the stool of such patients for occult blood would be good
clinical practice.
This study also suggests that for most patients with a colorectal
cancer there is a sufficient interval after symptoms are reported to
the doctor for a worthwhile improvement in the timeliness of
diagnosis to be possible. Such an improvement would require
doctors to identify that their patient may have cancer, and to
request appropriate investigation. This may be particularly
pertinent when the patient has mild anaemia. Even though the
duration of symptoms is unrelated to the outcome of the cancer,
it is impossible to construct an argument in favour of delayed
diagnosis.
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